619 results about "Serine" patented technology

The invention discloses a high-performance carbonyl reductase mutant and application thereof in synthesis of a series of chiral alcohols. The high-performance carbonyl reductase mutant is obtained by performing the following mutations on an amino acid sequence as shown in SEQ ID NO.2: the 69th alanine mutates into any one of lysine, leucine, aspartic acid or asparagine, and the 69th alanine mutates into any one of lysine, leucine, aspartic acid or asparagine; and / or the 100th glycine is mutated into any one of glutamic acid, serine, lysine or asparagine. Compared with a wild type enzyme, the thermal stability and the catalytic activity of the obtained mutant are remarkably improved, particularly, single point mutants Mut-A69N, Mut-G100E and Mut-G100N and a combined mutant Mut-A69N-G100N show excellent relative enzyme activity, thermal stability and substrate tolerance. The mutant has high catalytic activity and stability to various chiral alcohols, and the contradiction that the traditional carbonyl reductase is easy to inactivate at high temperature and the catalytic efficiency is difficult to achieve at the same time is solved. The invention provides an efficient and stable enzyme catalysis tool for green biological preparation of chiral drug intermediates.

The invention discloses a cyclic nonapeptide with repairing and anti-oxidation effects and application of the cyclic nonapeptide, the amino acid sequence of the cyclic nonapeptide is cyclic (arginine-glycine-aspartic acid-serine-arginine-lysine-valine-lysine-serine), the prepared cyclic nonapeptide has the repairing and anti-oxidation effects, and the cyclic nonapeptide has the repairing and anti-oxidation effects. The composition can be applied to preparation of cosmetics with repairing and / or anti-oxidation effects.

The invention discloses keratinase Phyto-Keratinase and application of the keratinase Phyto-Keratinase. The keratinase Phyto-Keratinase comprises the following components: (1) protease which is coded by a nucleotide sequence as shown in SEQ ID NO.1; and / or (2) protease which is derived from bacillus subtilis, is coded by a nucleic acid sequence with more than 98% of identity with the SEQ ID NO.1 nucleotide sequence and has the characteristic of hydrolyzing keratin. According to the plant keratinase Phyto-Keratinase disclosed by the invention, the Phyto-Keratinase (plant keratinase) produced by utilizing microbial fermentation is a serine proteolytic enzyme, is also a biocompatible cutinase, and is obtained by fermenting saccharomyces cerevisiae. Phyto-Keratinase provides a nitrogen source for the growth of plants (beans), and contains various amino acids (functional peptides) and special proteolytic enzymes derived from the plants at the same time. The Phyto-keratinase can provide the effects of resisting inflammation, removing cutin and providing nutrition for skin regeneration at the same time, can relieve various inflammations by inhibiting PAR-2 receptors, and has potential value in the fields of cosmetics, beauty medicine and environment.

The invention belongs to the technical field of biology, and particularly relates to application of serine in relieving heat stress of pleurotus ostreatus and a method. Under the heat stress condition, exogenous serine supply promotes pleurotus ostreatus hypha to recover growth, and the activity of antioxidant enzyme, the yield of sporocarp and the yield of nutrient substances are improved; when the activity of the PHGDH enzyme is inhibited, the serine synthesis is reduced; the hypha growth can be promoted by overexpressing the phgdh, and the enzymatic activity of the PHGDH can be improved; when acetyltransferases HAT, NAT1, NAT2 and NAT3 act on a K394 site of the PHGDH, the enzyme activity of the PHGDH can be improved, endogenous serine metabolism is activated to respond to heat stress, it is indicated that PHGDH-mediated serine metabolism plays an important role in corresponding heat stress of the pleurotus ostreatus, and the invention discloses a mechanism for improving heat resistance of the pleurotus ostreatus through the PHGDH-mediated serine metabolism. And a foundation can be laid for breeding high-temperature-resistant pleurotus ostreatus dominant strains.

The invention relates to the technical field of related drugs for nerve injury caused by heavy metal pollution, in particular to application of a compound for inhibiting phosphorylation of ARMC10 in preparation of drugs for antagonizing tin-induced nervous system injury. Exposure of trimethyltin chloride induces nerve cell mitochondrial dysfunction, and the key mechanism is ARMC10 serine 43 site abnormal phosphorylation. Phosphorylated protein causes excessive mitochondrial fission, membrane potential collapse and energy metabolism disorder, resulting in neuron damage. Based on the target spot, a compound for antagonizing tin-induced nervous system injury is obtained through screening, protein phosphorylation can be specifically inhibited, mitochondrial dynamic unbalance and dysfunction induced by trimethyltin chloride are effectively reversed, and neurotoxicity is relieved. According to the technical scheme, the technical problem that in the prior art, no medicine for effectively antagonizing tin-induced nervous system injury exists can be solved, and the compound has the application potential for treating the nervous system injury and cognitive impairment caused by tin exposure.

The invention relates to the technical field of functional food and biological medicine, in particular to a modified pseudo-ginseng exosome and an intestinal conditioning gel composition and application thereof. According to the gel beverage, an exosome derived from panax notoginseng callus cultured in a laboratory is used as a core active component, is modified through phosphatidylserine-aminated pectin-genipin and is embedded into a hydrogel matrix composed of carboxymethyl chitosan and sodium alginate, so that the exosome is protected from being degraded in the stomach, and the activity of the exosome in the stomach is improved. The exosome can be effectively released under the intestinal pH and flora environment, so that the targeted delivery of the intestinal tract is realized, and the preparation method is suitable for improving the intestinal inflammation and maintaining the intestinal health. The invention can effectively solve the technical problems of uncontrollable raw material quality and safety, low oral delivery stability and active ingredient availability and poor medication compliance of the existing plant exosome.

Among other things, provided herein are systems that replace the natural random integration activity of a retrovirus with site-specific integration machinery. This approach allows for a more precise targeting of a gene of interest into a human genome, e.g., for therapeutic purposes. The system may include integration-deficient retrovirus (e.g., lentivirus) (IDLV), in which the natural integration activity has been reduced (e.g., by mutation to the viral integrase polypeptide). Instead, the system may comprise a site-specific recombinase (e.g., a serine recombinase, e.g., a serine integrase) capable of directing insertion of a template DNA, or portion thereof, into a desired site in the human genome.

The invention discloses an amino acid composition for treating alopecia and application of the amino acid composition in preparation of a medicine for treating alopecia, and belongs to the field of medicine configuration products, the amino acid composition is composed of a targeting core intervention component and an auxiliary strengthening synergistic component, the targeting core intervention component is prepared from 30-50 parts of arginine, 50-155 parts of lysine and 50-120 parts of glutamic acid, and the auxiliary strengthening synergistic component is prepared from an auxiliary strengthening synergistic component and an auxiliary strengthening synergistic component. 10 to 40 parts of cysteine and 20 to 60 parts of leucine; the auxiliary strengthening synergistic component is prepared from 15 to 45 parts of tyrosine, 15 to 40 parts of glycine, 10 to 40 parts of glutamine, 20 to 35 parts of serine, 5 to 25 parts of alanine, 2 to 20 parts of aspartic acid and 15 to 35 parts of phenylalanine; the composition can be used as an active ingredient to be prepared into different dosage forms such as a pigmentum, a spray, an ointment and a liniment, is applied to prevention of alopecia and promotion of hair growth, and has a remarkable treatment effect.

According to the scheme, the invention provides the recombinant macrolide enzyme as well as the preparation method and the application thereof, the amino acid sequence of the recombinant macrolide enzyme is as shown in SEQ ID NO.1, and the recombinant macrolide enzyme is derived from an EreC esterase family of enterobacter hormaechei and is obtained through site-specific mutagenesis; the mutation sites are as follows: glutamic acid at the 44th site is mutated into asparagine, tyrosine at the 55th site is mutated into proline, proline at the 76th site is mutated into arginine, phenylalanine at the 153rd site is mutated into alanine, and serine at the 219th site is mutated into glutamic acid. The method is expected to remove macrolide antibiotic pollution, and has good economic benefits and practical values.

The invention relates to the technical field of technical gene detection, in particular to a recombinase and recognition site screening method and system based on structure classification prediction.The method comprises the steps that to-be-matched recombinase is obtained for structure resolution prediction.The functional domain of the to-be-matched recombinase is obtained; searching in a first database according to the functional domain, searching candidate recombinase of which the similarity meets a preset condition, and screening to obtain optimal recombinase; determining an interaction region of the current large serine recombinase and the target DNA sequence from a second database, and sequentially obtaining interaction amino acid sequences corresponding to the preferable recombinase; and matching with the amino acid characteristic sequence of the current large serine recombinase in the second database to obtain the target large serine recombinase with the highest similarity in the preferred recombinase and the corresponding recognition site sequence. According to the method, the structure of the large protein is subjected to structure comparison mining and splitting, and recognition site prediction is performed on interaction region amino acid characteristics, so that the research and development period is shortened, and the research and development cost is saved.

The present disclosure provides a recombinant Escherichia coli strain modified by metabolic engineering means and a method for producing L-homoserine by using the same. The strain, designated as Escherichia coli having a strain number of 13-XA, is deposited in China General Microbiological Culture Collection Center (CGMCC) with an accession number of CGMCC No. 25099, dated Jun. 16, 2022. With respect to the chromosome DNA thereof, one or more genes associated with fatty acid metabolism are knocked out or attenuated, and / or a promoter is replaced for enhancement; one or more genes associated with the L-homoserine metabolic pathway are knocked out or attenuated, and / or one or more genes associated with the L-homoserine metabolic pathway are overexpressed or enhanced, and / or one or more genes associated with the L-homoserine metabolic pathway are mutated.

The invention discloses a serine hydroxymethyltransferase mutant and an application thereof in production of L-serin.The serine hydroxymethyltransferase mutant with the specific enzyme activity remarkably improved is obtained by conducting saturated mutation on serine hydroxymethyltransferase from escherichia coli and conducting screening, and the serine hydroxymethyltransferase mutant is applied to synthesis of L-serine. The serine hydroxymethyltransferase disclosed by the invention can be used for effectively improving the efficiency of catalyzing glycine and formaldehyde to synthesize L-serine by using the serine hydroxymethyltransferase, reducing the enzyme dosage, remarkably reducing the production cost and reducing the separation difficulty of downstream products.

The invention discloses a preparation method of a nano-liposome coated NAD amino acid nutrient solution, and relates to the technical field of liposome amino acid nutrient solution preparation, the preparation method comprises the following steps: S1, preparing raw materials: S1.1, preparing NAD amino acid; s1.2, lecithin: using pure natural lecithin from soybeans and eggs; s1.3, preparing sodium hyaluronate: adopting sodium hyaluronate with low molecular weight; s1.4, preparing an amino acid compound, wherein the amino acid compound contains a plurality of essential amino acids, including glycine, serine and lysine; according to the mask, when the NAD amino acid nutrient solution wrapped by the nano-liposome is applied to the mask, the mask can more effectively permeate into the deep layer of the skin due to the excellent stability and biological activity of the NAD amino acid nutrient solution, and sufficient nutrition and moisture are provided for the skin; meanwhile, due to the strong anti-aging effect, the mask can remarkably improve the skin texture, reduce fine wrinkles and wrinkles, and make the skin more compact, smoother and elastic.

The invention belongs to the technical field of biology, and discloses a transaminase GabT1 mutant S106I, a construction method thereof and application of the transaminase GabT1 mutant S106I in biosynthesis of 1-deoxynojirimycin. According to the invention, the 106th serine near the molecular catalytic domain of the transaminase GabT1 derived from bacillus amyloliquefaciens is mutated into isoleucine in a site-directed mutagenesis manner, so that the catalytic efficiency of the transaminase GabT1 is remarkably improved, the problem that the catalytic efficiency of the transaminase GabT1 on fructose-6-phosphoric acid is not high at present is solved, and the application of the transaminase GabT1 to the fructose-6-phosphoric acid is promoted. The yield of 1-deoxynojirimycin synthesized by the mutant GabTS106I is increased by 43.87% compared with that of a wild type. The 1-deoxynojirimycin fermentation production capability of the transaminase GabT1 mutant and the engineering strain obtained by the invention is greatly improved, and the transaminase GabT1 mutant and the engineering strain have a good industrial application prospect.

A CVB virus expression vector comprising a PIV5 W3A viral genome comprising a mutation at amino acid residue S157 or S156 of the P / V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) with phenylalanine (F) or asparagine (N), and the SH gene has a deletion of the SH open reading frame or the entire SH gene transcription unit. The CVB virus expression vector expresses a heterologous polypeptide, including SARS-CoV-2 spike (S), and / or nucleocapsid (N) and / or membrane (M) proteins, RSV fusion protein (F), or other antigens.

The present invention relates to nuclear mitotic apparatus (NuMA) protein serine 395 (S395) phosphorylation inhibitor for use in preventing and / or treating cancer in a subject. The invention also relates to a pharmaceutical composition comprising a NuMA S395 phosphorylation inhibitor. Furthermore, the invention provides a method of screening for a candidate compound for preventing and / or treating cancer, and a method of detecting a dormant cancer cell in a subject. Corresponding methods of treating and / or preventing cancer are also provided.

The invention provides a single-chain and double-protein-expressed circular RNA construct and a preparation method and application thereof, and the single-chain and double-protein-expressed circular RNA construct comprises 5'and 3 'introns used for realizing RNA self-splicing and cyclization as a first kind of introns; the 5'and 3 'homologous arms are used as pairing sites in RNA molecules; the exon 1 and the exon 2, which are connected after being spliced, can be spliced and connected together under the action of the first type of introns to form a complete and continuous open reading frame; an interval sequence for providing spatial and adjustment sequence structures; the IRES is used for starting translation; a glycine-serine linker as a flexible linker; a green fluorescent protein for gene expression monitoring; a luciferase for producing light by a catalytic chemical reaction. All the advantages of the double-IRES system for generating natural complete protein are reserved, and the core defect of low efficiency can be thoroughly overcome.

Disclosed herein are engineered LSR sequences, compositions, and uses including in genome-editing systems and therapeutic compositions. The LSRs can facilitate nucleic acid recombination at particular attachment sites, using suitable donor sequences. The disclosed LSRs may be used to site-specifically recombine or integrate nucleic acid sequences for a variety of purposes, including treatment of human diseases.

To provide agents for promoting epidermal keratinocyte growth, filaggrin mRNA expression, serine palmitoyltransferase mRNA expression, involucrin expression or ATP production by finding substances having excellent activity in promoting epidermal keratinocyte growth, filaggrin mRNA expression, serine palmitoyltransferase mRNA expression, involucrin expression or ATP production.SOLUTION: An epidermal keratinocyte growth promoting agent of the invention comprises one or more effective ingredients selected from the group consisting of 2-ketoglutaric acid, 2-isopropyl malate, inosine 5'-monophosphoric acid, succinic acid, malic acid and pyruvic acid. Also, a filaggrin mRNA expression promotor, a serine palmitoyltransferase mRNA expression promotor, an involucrin expression promotor of the invention comprise, as an effective ingredient, 2-ketoglutaric acid. Further an ATP production promotor of the invention comprises 2-isopropyl malate as an effective ingredient.SELECTED DRAWING: None

The invention belongs to the technical field of biology, and discloses a biosynthesis method of L-homoserine. According to the biosynthesis method, L-homoserine is synthesized by taking L-aspartic acid and formaldehyde as substrates, aldolase and transaminase are adopted, and oxaloacetic acid decarboxylase can be optionally added to improve the efficiency of a catalytic system. The method can be realized through an in-vitro multi-enzyme catalysis system, and can also be completed in a manner of introducing a way into microorganisms. According to the method, methanol, formaldehyde and other carbon resources can be introduced to synthesize the L-homoserine with high value, the raw materials are low in price, and the whole synthesis method has the advantages of high atom utilization rate and high conversion rate.

The application discloses a beta-1,4-xylanase mutant and a construction method thereof, and comprises the following steps: constructing a beta-1,4-xylanase recombinant expression vector; introducing the recombinant vector pNZ8048-P5-XynA into a competent lactococcus lactis by using an electrotransformation technology to construct a wild-type expression vector; on the basis, designing and constructing a multi-site mutant recombinant plasmid by using a site-directed mutation method, wherein the eighth asparagine (Asn) of the beta-1,4-xylanase is mutated into tyrosine (Tyr), the 22nd serine (Ser) is mutated into proline (Pro), and the 59th alanine (Ala) is mutated into lysine (Lys); introducing the multi-site mutant recombinant plasmid into the competent lactococcus lactis to construct a heterologous expression strain of the mutant beta-1,4-xylanase (Mut-1); and stably obtaining the mutant xylanase beta-1,4-xylanase (Mut-1) with high activity by using a metal affinity chromatography (Ni 2+ ) method. The specific enzyme activity of the mutant reaches 1929.30±5.36 U / mg, and the optimal temperature is increased by 15 DEG C compared with that of the wild type.

The invention discloses a lipase mutant, an engineering bacterium and application of the lipase mutant in preparation of (2S, 3R)-p-methylsulfonylphenyl serine ethyl ester. The lipase mutant is obtained by performing single mutation or combined mutation on 67th, 115th or 400th amino acid of an amino acid sequence as shown in SEQ ID No.1. The invention further discloses a preparation method of the lipase mutant, the engineering bacterium and the application of the lipase mutant in preparation of (2S, 3R)-p-methylsulfonylphenyl serine ethyl ester. The lipase mutant provided by the invention has the advantages that the enzyme activity is obviously improved, the selectivity is not reduced, the reaction conversion rate of the lipase mutant serving as a catalyst reaches 50%, the required reaction time is obviously shortened by 1-7 hours, and the lipase mutant has more excellent catalytic activity. Under the optimal system, the conversion rate after 1000 mM of a substrate is split for 4 h reaches 50.5%, e.e.gt; therefore, a certain basis is provided for industrial preparation of optically pure (2S, 3R)-p-methylsulfonylphenyl serine ethyl ester.

The invention belongs to the technical field of organic synthesis, and particularly relates to a preparation method of a hydrogenated lecithin acyl serine intermediate. By selecting the specific deprotection agent, the generation of isomers can be effectively reduced, so that the high-purity hydrogenated lecithin acyl serine intermediate is obtained, and the method has the characteristics of simple post-treatment, low cost, environmental friendliness and the like.

The present disclosure relates to compositions comprising lipid nanoparticles (LNPs) configured for targeting dendritic cells. In particular, the present disclosure provides LNPs comprising a serine-based helper-lipid, a PEG lipid, an ionizable lipid, a cholesterol component, and one or more nucleic acids. The present disclosure provides use of the LNPs for the delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in various therapeutics, such as for the treatment of cancer or autoimmune diseases or prevention of infectious diseases. Finally, methods are provided for preparing such LNPs.

The application discloses a construction method and application of a genetically engineered corynebacterium glutamicum for synthesizing a bacteriochlorophyllide amino acid shinorine, and belongs to the field of genetic engineering and fermentation technology. The genetically engineered corynebacterium glutamicum is constructed by taking corynebacterium glutamicum ATCC 13032 as a host strain, knocking out a competitive pathway gene, integrating a key enzyme gene in multiple copies on a genome, knocking out an acid production pathway gene and a serine dehydrogenase gene, and expressing a gene cluster for synthesizing shinorine on a plasmid, so that the synthesis yield of shinorine in a microbial cell is improved. The strain can produce shinorine in a flask, and 1.12 g / L of shinorine can be accumulated in 72 hours. In fed-batch fermentation in a 50 L fermenter, the strain can be cultured to 8.6 g / L.

O-acyl homoserine hydrosulphide variants and uses thereof are provided.

The application provides a polypeptide, a plant immune elicitor and application thereof. The polypeptide has 10 or 11 amino acid residues; the amino acid at the first position of the polypeptide is serine, and the amino acids at the 9th and 10th positions are both cysteine; if the polypeptide has 11 amino acid residues, the amino acid at the 11th position of the polypeptide is asparagine. The polypeptide can solve the problem that there is no small peptide secreted by gramineae plants in the prior art, and is suitable for the field of plant immune elicitors.

Tolerogenic liposome-based compositions and uses thereof for treating immune disorders. The compositions include two populations of liposomes. The first population of liposomes has a size in the range from 2 to 200 nm, and the second population of liposomes has a size in the range from 500 to 2000 nm. The liposomes of the first and second populations carry one or more antigens. The liposomal membrane of each liposome in the first and second liposome populations include phosphatidylserine in an amount ranging from 20 to 60% by weight with respect to the total composition of the liposome's membrane.

A provided self-replicating mRNA is transcribed from an alphavirus backbone vector. The alphavirus backbone vector comprises gene sequences of alphavirus non-structural proteins nsP2, nsP3, nsP4, and mutated nsP1. A cysteine at position 492 of the mutated nsP1 is mutated into serine. The self-replicating mRNA has a higher expression level and a longer expression time for a target gene. The self-replicating mRNA is used for expressing IMP3, and can be prepared into a vaccine having good preventive and therapeutic effects on IMP3-positive tumors. Therefore, the present invention has good application prospects in drug and vaccine development.

The present disclosure describes PLPC-DB, an ultrapure phospholipoproteomic composition consisting of essential phospholipids, bioactive proteins, and intercellular regulatory factors, derived from the supernatant of peripheral blood mononuclear cells (PBMCs). This composition achieves a purity level exceeding 99% through a patented purification process that integrates high-speed advanced centrifugation and selective ultrafiltration, ensuring the structural stability and functional integrity of its bioactive components. PLPC-DB is optimized for advanced research and diagnostic applications, providing reproducibility, consistency, and safety across multicenter studies. The essential biomolecular components of PLPC-DB include phosphatidylcholine and phosphatidylserine, which contribute to membrane stability and intracellular signaling, while cell communication peptides enhance intercellular signaling, homeostatic regulation, and biochemical coordination. Structural and regulatory lipids support cell membrane biogenesis and functional stability, whereas adhesion and signaling proteins mediate cell-cell interactions and immune response coordination. Additionally, bioactive regulatory factors modulate immune and inflammatory responses, contributing to tissue regeneration and metabolic homeostasis.